Safety and efficacy of subcutaneous injection with HMI-115 versus placebo in endometriosis-associated pain in premenopausal women: a multicentre, double-blind, randomised, proof-of-concept phase 2 trial
1. 请及时下载文件确认是否正确, 系统将在 2026-03-25 14:32:22 删除文件
2. 如若文件有误请驳回应助文件, 求助状态即回到求助中
3. 如若文件正确请及时点击确认, 若超过时后系统自动默认为已完结
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接: https://www.sciencedirect.com/science/article/abs/pii/S3050503825000329
其他信息:
L Zhu, ZJ Chen, H Liu, G Wang, K Dynowski…
The Lancet Obstetrics …, 2025
thelancet.com
Background Endometriosis is a chronic disease characterised by dysmenorrhoea and pelvic pain. There is an urgent unmet need for non-hormonal therapies for endometriosis, particularly for women in their reproductive years. Dysregulation of prolactin signalling, including systemic hyperprolactinaemia, augmented endometrial prolactin synthesis, and aberrant prolactin receptor activation, are implicated in the pathogenesis of endometriosis. This proof-of-concept study assessed the safety and efficacy of HMI-115, a human …
